Sichenzia Ross Ference LLP Represents Boustead Securities, LLC as Underwriter to China SXT Pharmaceuticals, Inc.’s $10.2 Million U.S. Initial Public Offering

Press Release – New York, NY – January 4, 2019 – Sichenzia Ross Ference LLP congratulates China SXT Pharmaceuticals, Inc. (the “Company”) (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (“TCMPs”), on the final closing of its initial public offering on January 3, 2019. Together with the first closing on December 31, 2018, the Company raised approximately $10.2 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,546,275 ordinary shares at a public offering price of $4.00 per share. The shares are scheduled to commence trading on the NASDAQ Capital Market today at around 2:05 p.m. ET under the ticker symbol “SXTC.”

Boustead Securities, LLC acted as the sole underwriter for the offering and the Firm acted as legal counsel to the underwriter. The Sichenzia Ross Ference LLP team was led by Senior Partner and head of the Firm’s Asian Practice Group, Benjamin Tan.

“We are thrilled and honored to be part of China SXT Pharmaceuticals, Inc.’s successful IPO and offer our heartiest congratulations and best wishes to the Company,” said Mr. Benjamin Tan, Senior Partner at Sichenzia Ross Ference. “The completion of this successful IPO further cements Boustead Securities, LLC’s as an active leader in the US-China IPO field and we are proud to have represented them.”

Follow Sichenzia Ross Ference on LinkedIn.

• Author
• Recent Posts

Sichenzia Ross Ference Carmel LLP

Sichenzia Ross Ference Carmel LLP is a full service law firm with a nationally recognized corporate, securities and litigation practice that provides experienced representation in all matters involving the securities industry.  In addition to handling routine to complex commercial matters, SRFC’s renowned litigation department specializes in defending companies and individuals against all types of securities cases, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.  The litigation team has also brought defamation lawsuits against companies and individuals related to market manipulation.  Additionally, it represents individuals and companies in investigations by the Securities and Exchange Commission (SEC) and other regulatory bodies.  The litigation team has a robust practice representing brokers and broker-dealers in arbitrations before the Financial Industry Regulatory Authority (FINRA).  These arbitrations typically involve claims of unsuitability, churning, unauthorized trading and other allegations of broker misconduct.  Finally, SRF has a burgeoning expungement practice, where it represents brokers seeking to have negative and harmful customer complaints removed from their industry records.  The firm complements its core practice areas with an established commercial real estate and trusts and estates practice.

Visit SRFC's LinkedIn page

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

• Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.5 Million Public Offering - December 12, 2024
• Sichenzia Ross Ference Carmel LLP Represents New Era Helium in De-SPAC Transaction, Nasdaq Listing and up to $85 Million in Financing - December 9, 2024
• Sichenzia Ross Ference Carmel LLP represents Madison Global Partners, LLC in an Unsecured Senior Convertible Note and Warrant Offering up to $1 Million - December 6, 2024